Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis

Jul 13, 2022

Read More

Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited

Jun 27, 2022

Read More

Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

Jun 10, 2022

Read More

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Jun 03, 2022

Read More

Zai Lab’s Updated Statement on SEC Listing Matter

Jun 01, 2022

Read More

Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference

May 31, 2022

Read More

Zai Lab Announces Upcoming Presentations at June Investor Conferences

May 24, 2022

Read More

Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022

May 20, 2022

Read More